Datopotamab Deruxtecan,pembrolizumab
daiichi sankyo,merck
['lcsm,(-blcsm)', 'nsclc', 'lung', 'sclc', 'daiichisankyous']
tomorrow at #asco22, we will share information on a trial-in-progress, tropion-lung08, evaluating our investigational agent in metastatic #nsclc, a disease area with high unmet need. #lcsm 
Daiichi Sankyo US’s channel featuring our biopharmaceutical news, passion for innovation & compassion for patients.  See our guidelines: https://t.co/4iEAbpw1Wx